Company news

Roche Holding Ltd news in 2026

Roche Holding Ltd's news releases, calls and decks from 2026, newest first.

View company

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

April 13, 2026

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

March 30, 2026

Correction: Roche

March 24, 2026

Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

March 23, 2026

Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation

March 18, 2026

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

March 16, 2026

AI in Life Sciences Market, 2026-2040 Industry Trends and Global Forecasts - IBM, IQVIA and Oracle Lead Data Platforms While Roche, Pfizer and AI Startups Accelerate Drug Discovery Innovation

March 13, 2026

FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer

March 12, 2026

Roche Annual General Meeting 2026

March 10, 2026

Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

March 9, 2026

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

March 6, 2026

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

March 5, 2026

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

March 5, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

March 2, 2026

Volta Labs Ignites AGBT 2026 with Major Product Launches and Industry-Shaping Partnerships

February 26, 2026

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

February 20, 2026

Zealand Pharma Announces Financial Results for the Full Year 2025

February 19, 2026

Change to the Roche Enlarged Corporate Executive Committee

February 17, 2026

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

February 16, 2026

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

February 7, 2026

ChemoMetec enters Letter of Intent with Roche Diagnostics

February 4, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

January 29, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

January 27, 2026

Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor

January 26, 2026

Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility

January 20, 2026

Cytespace Africa Labs Expands Molecular Testing Capacity to Advance Clinical Trials Across Sub-Saharan Africa

January 20, 2026

Frédéric Prince to Succeed Christian Loss, Effective January 1st, 2026

January 2, 2026

← Newer news releases

Calls in 2026

Decks in 2026